Eric Venker Sells 176,900 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 176,900 shares of the company’s stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00. Following the completion of the sale, the chief operating officer now owns 668,680 shares in the company, valued at approximately $7,903,797.60. This trade represents a 20.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Trading Up 3.5 %

ROIV opened at $11.83 on Thursday. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06. The company has a market capitalization of $8.61 billion, a PE ratio of 2.09 and a beta of 1.25. The firm’s 50 day simple moving average is $11.91 and its two-hundred day simple moving average is $11.55.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ROIV. Mutual of America Capital Management LLC raised its position in shares of Roivant Sciences by 0.4% during the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after purchasing an additional 1,142 shares during the period. Acadian Asset Management LLC grew its stake in shares of Roivant Sciences by 23.2% in the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock worth $89,000 after buying an additional 1,603 shares in the last quarter. Covestor Ltd grew its stake in shares of Roivant Sciences by 9.1% in the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after buying an additional 1,605 shares in the last quarter. US Bancorp DE boosted its stake in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares during the period. Finally, Quarry LP boosted its stake in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ROIV shares. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Bank of America raised their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.